Literature DB >> 11921286

Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.

Sarah V Williams1, Kathryn D Sibley, Alison M Davies, Hiroyuki Nishiyama, Nick Hornigold, Jane Coulter, Wendy J Kennedy, Amy Skilleter, Tomonori Habuchi, Margaret A Knowles.   

Abstract

Underrepresentation of chromosome 9 is a common finding in bladder cancer. Frequent loss of the whole chromosome suggests the presence of at least one relevant tumor suppressor gene on each arm. Candidate regions identified by loss of heterozygosity (LOH) analysis include a region at 9p21 containing CDKN2A, which encodes p16 and p14(ARF), a large region at 9q12-31 including PTCH and many other genes, a small region at 9q32-33, which includes the DBCCR1 gene, and a region at 9q34 including the TSC1 gene. Experimental replacement of genes or chromosomes into tumor cells with appropriate deletions or mutations represents an important approach to test the functional significance of candidate tumor suppressor genes. Loss of an entire copy of chromosome 9 in many bladder tumor cell lines provides no indication of which gene or genes are affected, and selection of appropriate recipient cells for gene replacement is difficult. We have investigated three candidate tumor suppressor genes on chromosome 9 (CDKN2A, DBCCR1, and TSC1), at the DNA level and by expression analysis in a panel of bladder tumor cell lines, many of which have probable LOH along the length of the chromosome, as indicated by homozygosity for multiple polymorphic markers. Cytogenetically, we found no reduction in the numbers of chromosomes 9 relative to total chromosome count. Homozygous deletion of the CDKN2A locus was frequent but homozygous deletion of TSC1 was not found. A new cell line, DSH1, derived from a pT1G2 transitional cell carcinoma with known homozygous deletion of DBCCR1, is described. This study identifies suitable cell lines for future functional analysis of both CDKN2A and DBCCR1. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11921286     DOI: 10.1002/gcc.10050

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  The importance of clinical application of molecular biomarkers in bladder cancer detection.

Authors:  Raluca Dumache; Maria Puiu; Dana David; Marinela Popovici; Adriana Kaycsa; Serban Negru; Florin Miclea
Journal:  Maedica (Buchar)       Date:  2010-04

2.  Loss and gain of chromosome 5 controls growth of Candida albicans on sorbose due to dispersed redundant negative regulators.

Authors:  M Anaul Kabir; Ausaf Ahmad; Jay R Greenberg; Ying-Kai Wang; Elena Rustchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-11       Impact factor: 11.205

3.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

4.  Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.

Authors:  Carl D Morrison; Pengyuan Liu; Anna Woloszynska-Read; Jianmin Zhang; Wei Luo; Maochun Qin; Wiam Bshara; Jeffrey M Conroy; Linda Sabatini; Peter Vedell; Donghai Xiong; Song Liu; Jianmin Wang; He Shen; Yinwei Li; Angela R Omilian; Annette Hill; Karen Head; Khurshid Guru; Dimiter Kunnev; Robert Leach; Kevin H Eng; Christopher Darlak; Christopher Hoeflich; Srividya Veeranki; Sean Glenn; Ming You; Steven C Pruitt; Candace S Johnson; Donald L Trump
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

5.  Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.

Authors:  David Lindgren; Gottfrid Sjödahl; Martin Lauss; Johan Staaf; Gunilla Chebil; Kristina Lövgren; Sigurdur Gudjonsson; Fredrik Liedberg; Oliver Patschan; Wiking Månsson; Mårten Fernö; Mattias Höglund
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

6.  A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder.

Authors:  Hans-Helge Seifert; Andrea Meyer; Marcus V Cronauer; Jiri Hatina; Mirko Müller; Harald Rieder; Michele J Hoffmann; Rolf Ackermann; Wolfgang A Schulz
Journal:  World J Urol       Date:  2007-04-18       Impact factor: 3.661

7.  Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors.

Authors:  Markus Heidenblad; David Lindgren; Tord Jonson; Fredrik Liedberg; Srinivas Veerla; Gunilla Chebil; Sigurdur Gudjonsson; Ake Borg; Wiking Månsson; Mattias Höglund
Journal:  BMC Med Genomics       Date:  2008-01-31       Impact factor: 3.063

8.  Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells.

Authors:  Ryuji Matsumoto; Masumi Tsuda; Kazuhiko Yoshida; Mishie Tanino; Taichi Kimura; Hiroshi Nishihara; Takashige Abe; Nobuo Shinohara; Katsuya Nonomura; Shinya Tanaka
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.